Daiichi Sankyo and ArQule Enter Into Strategic R&D Partnership to Progress Novel Compounds to Target Cancer
Product Development Agreement Focused on ARQ 197, c-Met Inhibitor,
13-Nov-2008 -
ArQule, Inc. and Daiichi Sankyo Co., Ltd. announced that they have entered into two agreements that form the basis of a strategic relationship for the development and discovery of novel oncology therapeutics. ArQule and Daiichi Sankyo will co-develop ARQ 197, a proprietary, orally administered, ...
China
clinical trials
Daiichi Sankyo
+5